0001209191-23-039508.txt : 20230623
0001209191-23-039508.hdr.sgml : 20230623
20230623182750
ACCESSION NUMBER: 0001209191-23-039508
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230621
FILED AS OF DATE: 20230623
DATE AS OF CHANGE: 20230623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rochlin Kate
CENTRAL INDEX KEY: 0001898521
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39692
FILM NUMBER: 231039025
MAIL ADDRESS:
STREET 1: IN8BIO, INC.
STREET 2: EMPIRE STATE BUILDING, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IN8BIO, INC.
CENTRAL INDEX KEY: 0001740279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 825462585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: (646) 600-6438
MAIL ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: Incysus Therapeutics, Inc.
DATE OF NAME CHANGE: 20180510
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-21
0
0001740279
IN8BIO, INC.
INAB
0001898521
Rochlin Kate
C/O IN8BIO, INC.
350 5TH AVE. SUITE 5330
NEW YORK
NY
10118
0
1
0
0
Chief Operating Officer
0
Employee Stock Option (right to buy)
2.01
2023-06-21
4
A
0
67800
0.00
A
2033-06-21
Common Stock
67800
67800
D
Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Jason Minio, Attorney-in-Fact
2023-06-23